Dose intensity in small cell lung cancer.
dc.contributor.author | Thatcher, Nick | |
dc.contributor.author | Lee, Siow Ming | |
dc.contributor.author | Woll, Penella J | |
dc.contributor.author | Middleton, Mark R | |
dc.contributor.author | Anderson, Heather | |
dc.contributor.author | Burt, Paul A | |
dc.contributor.author | Stout, Ronald | |
dc.date.accessioned | 2010-02-09T16:48:28Z | |
dc.date.available | 2010-02-09T16:48:28Z | |
dc.date.issued | 1998-04 | |
dc.identifier.citation | Dose intensity in small cell lung cancer. 1998, 25 (2 Suppl 4):12-8; discussion 45-8 Semin. Oncol. | en |
dc.identifier.issn | 0093-7754 | |
dc.identifier.pmid | 9578057 | |
dc.identifier.uri | http://hdl.handle.net/10541/91675 | |
dc.description.abstract | Evidence from preclinical models and from clinical trials describing the importance of dose intensity in securing a better treatment outcome is reviewed. Recent randomized trials have shown statistically significant survival benefits with higher-dose, accelerated chemotherapy regimens with and without granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. The novel use of peripheral blood progenitor cells contained in whole blood autotransfusions, which allow a marked increase in dose intensity of an ifosfamide/carboplatin/etoposide regimen, could provide a much easier method of delivering dose-intensive chemotherapy than previously available. | |
dc.language.iso | en | en |
dc.subject | Lung Cancer | en |
dc.subject | Haematopoietic Stem Cell Transplantation | en |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols | |
dc.subject.mesh | Carcinoma, Small Cell | |
dc.subject.mesh | Chemotherapy, Adjuvant | |
dc.subject.mesh | Clinical Trials as Topic | |
dc.subject.mesh | Granulocyte Colony-Stimulating Factor | |
dc.subject.mesh | Granulocyte-Macrophage Colony-Stimulating Factor | |
dc.subject.mesh | Hematopoietic Stem Cell Transplantation | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Lung Neoplasms | |
dc.title | Dose intensity in small cell lung cancer. | en |
dc.type | Article | en |
dc.contributor.department | CRC Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK. | en |
dc.identifier.journal | Seminars in Oncology | en |
html.description.abstract | Evidence from preclinical models and from clinical trials describing the importance of dose intensity in securing a better treatment outcome is reviewed. Recent randomized trials have shown statistically significant survival benefits with higher-dose, accelerated chemotherapy regimens with and without granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. The novel use of peripheral blood progenitor cells contained in whole blood autotransfusions, which allow a marked increase in dose intensity of an ifosfamide/carboplatin/etoposide regimen, could provide a much easier method of delivering dose-intensive chemotherapy than previously available. |